Live feed08:32:00·14mPRReleasevia QuantisnowNiagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)ByQuantisnow·Wall Street's wire, on your screen.NAGE· Niagen Bioscience Inc.Health Care
